Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China
Therapeutic Advances in Medical Oncology · 2024-01 · 16
DOI: 10.1177/17588359241242607 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 10.04.2024. Verfasst von Wenshu Qu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Affiliated Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jiangsu Hengrui Medicine.
Abstract (Originalsprache)
Background
Skin toxicities are the most common adverse events related to immunotherapy, such as reactive cutaneous capillary endothelial proliferation (RCCEP) following treatment with the anti-programmed cell death-1 antibody camrelizumab.
Objective
This study aimed to comprehensively analyze the clinical features and prognostic value of RCCEP in patients with malignancies who received camrelizumab alone (Camre) or in combination with the angiogenesis-targeted agent apatinib (Camre-Apa) or chemotherapy (Camre-Chemo).
Design
A large-scale pooled analysis.
Methods
Individual patient-level data were derived from 10 clinical trials of camrelizumab monotherapy, camrelizumab plus apatinib, or camrelizumab plus chemotherapy ( n = 1305).
Results
RCCEP occurred in 77.0% (516/670) of patients with Camre, 23.6% (70/296) with Camre-Apa, and 67.8% (230/339) with Camre-Chemo. Most RCCEP lesions were grade 1 or 2 in severity. The median time to onset was 0.8 months [interquartile range (IQR), 0.6–1.2] with Camre, 5.0 months (IQR, 2.7–8.0) with Camre-Apa, and 1.6 months (IQR, 1.0–4.2) with Camre-Chemo; and the median duration was 4.8 months (IQR, 2.6–8.8), 4.4 months (IQR, 1.7–8.9), and 7.2 months (IQR, 4.1–14.3), respectively. In all the three groups, patients with RCCEP showed significantly better clinical outcomes compared with those without [objective response rate: 23.8% versus 1.9% with Camre, 48.6% versus 21.2% with Camre-Apa, and 78.7% versus 54.1% with Camre-Chemo; median progression-free survival: 3.2 versus 1.7 months (hazard ratio (HR) = 0.36), 10.2 versus 4.5 months (HR = 0.39), and 12.7 versus 7.3 months (HR = 0.38); median overall survival: 13.3 versus 3.8 months (HR = 0.34), 29.2 versus 13.5 months (HR = 0.46), and not reached versus 12.8 months (HR = 0.19); all p < 0.0001].
Conclusion
Although RCCEP occurred frequently with camrelizumab, most lesions were mild and self-limiting. The occurrence of RCCEP was strongly associated with the antitumor activity and survival of camrelizumab, both as monotherapy and in combination therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Affiliated Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Medical Oncology, Affiliated Jinling Hospital, Nanjing University of Chinese Medicine, No. 34, 34 Biao, Yanggongjing Street, Nanjing 210002, China.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
Förderung
- Jiangsu Hengrui Medicine
Zitieren
APA
Qu, W., Wang, F., Qin, S., Sun, Y., & Huang, C. (2024). Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241242607
Vancouver
Qu W, Wang F, Qin S, Sun Y, Huang C. Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241242607
BibTeX
@article{Qu2024,
author = {Qu, Wenshu and Wang, Feng and Qin, Shukui and Sun, Yuqi and Huang, Chuanpei},
title = {Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China},
journal = {Therapeutic Advances in Medical Oncology},
year = {2024},
volume = {16},
doi = {10.1177/17588359241242607}
}
EUVIMED